（文章来源：证券日报） 证券日报网讯 8月14日晚间，西点药业发布2025年半年度报告摘要称，公司2025年半年度实现营业收入 为128，311，809.27元，同比下降0.51%；实现归属于上市公司股东的净利润为24，944，585.08元，同 比增长2.02%。 ...

（文章来源：证券日报） 证券日报网讯 8月14日晚间，西点药业发布公告称，公司第八届董事会第十二次会议审议通过了《关于 召开的议案》等多项议案。 ...

西点药业2025半年报 ...

Core Insights - The company reported a slight decrease in revenue but an increase in net profit, indicating effective cost management and market expansion strategies [1] - The company focuses on the development and production of chemical raw materials and formulations, particularly in the fields of chronic disease treatment, iron supplementation, and mental health [1][2] Financial Performance - The company achieved operating revenue of 128 million yuan, a year-on-year decrease of 0.51% [1] - Net profit attributable to shareholders was 24.94 million yuan, a year-on-year increase of 2.02% [1] - The net profit after deducting non-recurring gains and losses was 23.39 million yuan, reflecting a year-on-year growth of 12.26% [1] - Basic earnings per share were reported at 0.33 yuan [1] Product Development - The company’s core product, Ruixiangsu capsules, is a treatment for circulatory disorders and has seen sales growth due to technological innovation and patent developments [2] - The company is the only domestic producer of Ruixiangsu raw materials and capsules, and is expanding its clinical applications to include diabetic complications [2] - In the field of antipsychotic medications, the company has launched the full range of Risperidone orally disintegrating tablets, enhancing its market share [3] Market Strategy - The company is leveraging its integrated "raw materials + formulations" model to optimize production processes and ensure high-quality standards [3] - It is actively participating in national and regional procurement activities to expand market share for its antidepressant products [3] - The company aims to extend its production capabilities into iron supplementation and multi-element tablets, enhancing its competitive strength and profitability [3]

Group 1 - Tongda Power achieved a net profit of 42.64 million yuan in the first half of 2025, a year-on-year increase of 32.49% [1] - The company reported an operating income of 971 million yuan, up 22.07% year-on-year [1] - Basic earnings per share were 0.26 yuan [1] Group 2 - Hengshen New Materials reported a net loss of 36.70 million yuan in the first half of 2025, compared to a loss of 10.37 million yuan in the same period last year [2][3] - The company's operating income decreased by 24.84% to 1.22 billion yuan [2] Group 3 - Yiming Pharmaceutical's net profit was 37.56 million yuan, down 5.27% year-on-year [4] - The company experienced an 11.52% decline in operating income, totaling 311 million yuan [4] - Basic earnings per share were 0.20 yuan [4] Group 4 - Wangsu Technology achieved a net profit of 37.30 million yuan, a year-on-year increase of 25.33% [5] - The company's operating income was 2.35 billion yuan, up 2.19% year-on-year [5] - Basic earnings per share were 0.1524 yuan [5] Group 5 - Alloy Investment reported a net profit of 4.58 million yuan, a year-on-year increase of 44.12% [6] - The company achieved an operating income of 164 million yuan, up 73.46% year-on-year [6] - Basic earnings per share were 0.0119 yuan [6] Group 6 - Yifan Pharmaceutical's net profit was 30.40 million yuan, a year-on-year increase of 19.91% [8] - The company's operating income was 2.635 billion yuan, up 0.11% year-on-year [8] - Basic earnings per share were 0.25 yuan [8] Group 7 - Guoyao Yizhi reported a net profit of 66.60 million yuan, a year-on-year decrease of 10.43% [9] - The company's operating income was 36.797 billion yuan, down 2.62% year-on-year [9] - Basic earnings per share were 1.20 yuan [9] Group 8 - Hanjia Design expects a net profit of 15 to 16.5 million yuan, a year-on-year increase of 303.20% to 343.52% [10] - The company anticipates a net profit excluding non-recurring gains and losses of 14.5 to 17.5 million yuan, a year-on-year increase of 867.05% to 1067.13% [10] Group 9 - Gansu Energy Chemical announced the resumption of production at its Jinhe Coal Mine after passing safety inspections [16] Group 10 - Chuanjin Nuo reported a net profit of 177 million yuan, a year-on-year increase of 166.51% [18] - The company's operating income was 1.744 billion yuan, up 27.91% year-on-year [18] - Basic earnings per share were 0.6457 yuan [18] Group 11 - Yachuang Electronics achieved a net profit of 40.82 million yuan, a year-on-year increase of 1.47% [19] - The company's operating income was 2.847 billion yuan, up 125.74% year-on-year [19] - Basic earnings per share were 0.29 yuan [19] Group 12 - Yiheda reported a net profit of 282 million yuan, a year-on-year increase of 26.49% [14] - The company's operating income was 1.461 billion yuan, up 18.70% year-on-year [14] - Basic earnings per share were 0.44 yuan [14] Group 13 - Hatao Technology reported a net profit of 38 million yuan, a year-on-year increase of 233.08% [33] - The company's operating income was 1.475 billion yuan, up 1.12% year-on-year [33] - Basic earnings per share were 0.18 yuan [33] Group 14 - Anlu Technology announced that shareholders plan to reduce their holdings by no more than 3.25% of the company's shares [35] Group 15 - Baolidi reported a net profit of 63.81 million yuan, a year-on-year increase of 15.19% [36] - The company's operating income was 676 million yuan, up 1.47% year-on-year [36] - Basic earnings per share were 0.36 yuan [36] Group 16 - Harta Technology reported a net profit of 33.50 million yuan, a year-on-year increase of 55.61% [38] - The company's operating income was 335 million yuan, up 22.54% year-on-year [38] - Basic earnings per share were 0.0698 yuan [38] Group 17 - Huaxia Biological's controlling shareholder received a loan commitment of up to 250 million yuan from China Merchants Bank [58]

（文章来源：每日经济新闻） 2024年1至12月份，西点药业的营业收入构成为：医药占比99.55%，其他业务占比0.45%。 西点药业（SZ 301130，收盘价：34.1元）8月14日晚间发布公告称，公司第八届第十二次董事会会议于 2025年8月14日在吉林省长春市卫星路1471号公司会议室召开。会议审议了《关于公司全文及其摘要的 议案》等文件。 ...

Group 1 - The core viewpoint of the article is that West Point Pharmaceutical reported its semi-annual performance, showing a slight decline in revenue but an increase in net profit and earnings per share [2] Group 2 - For the first half of 2025, the company's operating revenue was approximately 128 million yuan, a year-on-year decrease of 0.51% [2] - The net profit attributable to shareholders of the listed company was approximately 24.94 million yuan, reflecting a year-on-year increase of 2.02% [2] - The basic earnings per share were 0.3261 yuan, which represents a year-on-year increase of 7.77% [2]

Fundraising Overview - The company raised a total of RMB 455.5322 million through its initial public offering, with a net amount of RMB 390.9331 million after deducting various issuance costs [1][2] - The funds were raised by issuing 20.200986 million shares at a price of RMB 22.55 per share [1] Fund Utilization and Balance - As of December 31, 2022, the company had a remaining balance of RMB 336.43 million in its fundraising account, with RMB 4.70846 million used for projects and RMB 1.69811 million for issuance costs [2] - By December 31, 2023, the remaining balance was RMB 236.3034 million, with RMB 9.35421 million utilized for projects [2] - As of December 31, 2024, the remaining balance was RMB 137.4138 million, with RMB 8.77753 million used for projects [2] - As of June 30, 2025, the remaining balance was RMB 114.5452 million, with RMB 2.37295 million utilized for projects [2] Fund Management - The company has established a fundraising management system to ensure the effective use of funds and protect investor rights [3] - Funds are stored in designated bank accounts, and a tripartite supervision agreement has been signed with the underwriter and banks [3] Project Completion and Remaining Payments - Several projects funded by the raised capital, including the R&D center and marketing network construction, have been completed, with remaining payments totaling RMB 30.1286 million [2][3] - The company has used part of the raised funds to replace self-raised funds for issuance costs, amounting to RMB 4.6433 million [6][11] Idle Fund Management - The company has approved the use of idle funds for cash management, with a limit of RMB 100 million [5][6] - As of June 30, 2025, RMB 42 million of idle funds were allocated for cash management [12]

证券代码：301130 证券简称：西点药业 公告编号：2025-056 吉林省西点药业科技发展股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 8 月 度的议案》。本次关于部分制度的修订事项尚需提交股东大会审议。现将有关情 况公告如下： 为进一步促进公司规范运作，建立健全内部管理机制，根据《中华人民共和 国公司法》 《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》 《深 《关联交易管理制度》 《回购股份 管理制度》 《累积投票制实施细则》 《募集资金管理制度》 《内部审计制度》 《内幕 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上 市公司章程指引》《上市公司股东会规则》等法律、法规及规范性文件的最新规 定，结合公司实际情况，现对公司《独立董事工作制度》《独立董事专门会议规 则》 《对外担保管理制度》 《对外投资管理制度》 特此公告。 吉林省西点药业科技发展股份有限公司董事会 信息知情人登记管理制度》《投资者关系管理制度》《委托理财管理 ...

Group 1 - The company is Jilin Xidian Pharmaceutical Technology Development Co., Ltd. [1] - The document includes financial data for the year 2025, specifically for the first half of the year [2] - The financial data includes details on fund occupation and related party transactions [2] Group 2 - The document outlines non-operating fund occupation and the reasons for such occupations [2] - It specifies the amounts involved in fund occupation and the interest associated with these transactions [2] - The document also mentions the relationships with controlling shareholders and affiliated companies [2]